Profil
Pascal Lemaire has held director positions at Symphogen A, Servier Canada, Inc., and GeNeuro SA (Switzerland).
Aktive Positionen von Pascal Lemaire
| Unternehmen | Position | Beginn |
|---|---|---|
| GENEURO SA | Direktor/Vorstandsmitglied | 18.03.2024 |
Servier Canada, Inc.
 Servier Canada, Inc. Pharmaceuticals: MajorHealth Technology Servier Canada, Inc. provides healthcare services. It manufactures pharmaceuticals for cardiology, diabetes, depression, venous disease and menopause. The company was founded in 1978 and is headquartered in Quebec, Canada. | Direktor/Vorstandsmitglied | - |
Symphogen A/S
 Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | Direktor/Vorstandsmitglied | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| GENEURO SA | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Servier Canada, Inc.
Servier Canada, Inc. Pharmaceuticals: MajorHealth Technology Servier Canada, Inc. provides healthcare services. It manufactures pharmaceuticals for cardiology, diabetes, depression, venous disease and menopause. The company was founded in 1978 and is headquartered in Quebec, Canada. | Health Technology |
Symphogen A/S
Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | Health Technology |
